OverviewYale has an active transplant program and provides continuity of care to more than 700 outpatients with heart failure.
Heart failure and transplant-related research at Yale consists of ten ongoing studies, including investigations of:
Left ventricular assist devices/systems (LVAD/LVAS)
- DuraHeart LVAS – Evaluation of the safety and effectiveness of the DuraHeart™ left ventricular assist device in patients with advanced heart failure
- DuraHeart-2 Bridge to Transplant LVAD Trial
- Levitronix CentriMag VAS Failure-to-Wean from Cardiopulmonary Bypass Trial – Evaluation of the safety and effectiveness of the CentriMag ventricular assist system in patients who have experienced heart failure during surgery and cannot be removed from cardiac bypass.
- Heartware Destination Therapy Trial – Trial of an LVAD as destination therapy in patients with advanced heart failure who have failed medical therapy and are not eligible for cardiac transplantation
- INTERMACS - A national registry for patients receiving mechanical circulatory support device therapy to treat advanced heart failure (a joint effort of the NHLBI, CMS, and FDA)
Congestive Heart Failure
- HEART MATE III - New VAD Device
- GUIDE IT - Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure
- FIX HF - Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects with Moderate-to-Severe Heart Failure with Ejection Fraction between 25%and 45%: (FIX-HF-5C)
- Parachute - A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System (PARACHUTE IV)
- WISDOM -An Intervention to Improve Implantable Cardioverter-Defibrillator Deactivation Conversations